TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11319676

Group type: EXPERIMENTAL
Intervention: Device (n = 32)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Walkman (n = 29)
Number of subjects: 61
Study: 30882239

Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 3584

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3584
Study: 30340777

Group type: EXPERIMENTAL
Intervention: Endovascular coiling (EV)
Number of subjects: 351

Group type: COMPARATOR
Intervention: Microsurgical clipping (MS)
Number of subjects: 351
Study: 26491112

Group type: EXPERIMENTAL
Intervention: Morphine (5 mg)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 25362221

Group type: EXPERIMENTAL
Intervention: Raloxifene, 60 mg/d for 8 months
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo for 8 months
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Raloxifene and Placebo
Number of subjects: 60
Study: 22300538

Group type: EXPERIMENTAL
Intervention: Everolimus
Number of subjects: 127

Group type: COMPARATOR
Intervention: Cyclosporine
Number of subjects: 127
Study: 20822213

Group type: EXPERIMENTAL
Intervention: Basic numerical cognition
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: Domain-general abilities
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: Counting span
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: Language, attentive behavior, nonverbal problem solving, and listening span
Number of subjects: 280
Study: 17369678

Group type: EXPERIMENTAL
Intervention: Band ligation
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Injection sclerotherapy
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (normal age-matched controls)
Number of subjects: 32
Study: 15621317

Group type: EXPERIMENTAL
Intervention: Neutral posture for flexion
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Neutral posture for extension
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Increasing angular deviation of the neck
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Comparison of males and females
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Overall flexion-extension ratio
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Neutral posture vs flexion and extension
Number of subjects: 39
Study: 11979650

Group type: EXPERIMENTAL
Intervention: Topical mupirocin (Bactroban) applied to nares and catheter exit site
Number of subjects: 2

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 2
Study: 10023498

Group type: EXPERIMENTAL
Intervention: Testosterone cypionate 100 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Testosterone cypionate 250 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Testosterone cypionate 500 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 7751428

Group type: EXPERIMENTAL
Intervention: Local phentolamine (administered directly into a preconstricted hand vein)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Systemic phentolamine (administered intravenously)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (vehicle solutions)
Number of subjects: 0
Study: 2321541

Group type: EXPERIMENTAL
Intervention: Caffeine (3.3 mg/kg)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 43755

Group type: EXPERIMENTAL
Intervention: Metoclopramide 40 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Haloperidol 5 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Haloperidol 10 mg
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 8
Study: 31338773

Group type: EXPERIMENTAL
Intervention: PF-06439535 plus paclitaxel and carboplatin
Number of subjects: 719

Group type: COMPARATOR
Intervention: Bevacizumab-EU plus paclitaxel and carboplatin
Number of subjects: 719

Group type: EXPERIMENTAL
Intervention: PF-06439535 and Bevacizumab-EU
Number of subjects: 719
Study: 28475467

Group type: EXPERIMENTAL
Intervention: Time-pressure condition
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Compliant-only analysis
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Intent-to-treat analysis
Number of subjects: 21

Group type: COMPARATOR
Intervention: Forced-delay condition
Number of subjects: 21
Study: 25204277

Group type: EXPERIMENTAL
Intervention: Acute tryptophan depletion (ATD)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 23370902

Group type: EXPERIMENTAL
Intervention: 0.5-mg intravitreal ranibizumab
Number of subjects: 261

Group type: COMPARATOR
Intervention: Intravitreal saline
Number of subjects: 261
Study: 21550313

Group type: EXPERIMENTAL
Intervention: Cefotaxime infusion plus paracetamol
Number of subjects: 723

Group type: EXPERIMENTAL
Intervention: Cefotaxime infusion
Number of subjects: 723

Group type: EXPERIMENTAL
Intervention: Cefotaxime bolus plus paracetamol
Number of subjects: 723

Group type: EXPERIMENTAL
Intervention: Cefotaxime bolus
Number of subjects: 723

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 723
Study: 19189066

Group type: EXPERIMENTAL
Intervention: High-dose antithrombin (AT) without simultaneous heparin treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-dose antithrombin (AT) without simultaneous heparin treatment in risk group grade II patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 17536000

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) at 0.06 mg/kg.d for 2 years (group I)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Growth hormone (GH) for 12 months after 12 months of no treatment (group II)
Number of subjects: 76
Study: 14990550

Group type: EXPERIMENTAL
Intervention: 15 ml/kg of 0.9% NaCl infusion over 60 min
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 15 degrees head-down position
Number of subjects: 18

Group type: COMPARATOR
Intervention: 15 degrees feet-down position
Number of subjects: 18
Study: 11810323

Group type: EXPERIMENTAL
Intervention: Ropivacaine (150 mg)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Morphine (1 mg or 5 mg)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Combination of 5 mg morphine and 75 mg ropivacaine
Number of subjects: 135

Group type: COMPARATOR
Intervention: Control group (isotonic saline)
Number of subjects: 135
Study: 9732164

Group type: EXPERIMENTAL
Intervention: cetirizine 10 mg
Number of subjects: 18

Group type: COMPARATOR
Intervention: ebastine 10 mg
Number of subjects: 18
Study: 8054406

Group type: EXPERIMENTAL
Intervention: Lisuride (up to 4.0 mg daily for 3 weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 2845239

Group type: EXPERIMENTAL
Intervention: Theophylline
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Salbutamol
Number of subjects: 12
Study: 29993216

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (10%)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 60
Study: 26010873

Group type: EXPERIMENTAL
Intervention: Individuals with CF
Number of subjects: 0

Group type: COMPARATOR
Intervention: Peers with experience of CF
Number of subjects: 0

Group type: COMPARATOR
Intervention: Peers without experience of CF
Number of subjects: 0
Study: 26510448

Group type: EXPERIMENTAL
Intervention: Metformin 500 mg twice daily for 24 weeks
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66

Group type: COMPARATOR
Intervention: Metformin vs Placebo
Number of subjects: 66
Study: 24027289

Group type: EXPERIMENTAL
Intervention: Cognitive training coupled with parietal tRNS (transcranial random noise stimulation)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Cognitive training without stimulation
Number of subjects: 40

Group type: COMPARATOR
Intervention: Stimulation without cognitive training
Number of subjects: 40

Group type: COMPARATOR
Intervention: Cognitive training coupled to stimulation of a control site (motor areas)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Cognitive training with parietal tRNS
Number of subjects: 40
Study: 21606960

Group type: EXPERIMENTAL
Intervention: Flavopiridol
Number of subjects: 116
Study: 18340100

Group type: EXPERIMENTAL
Intervention: Transcranial continuous insonation using a 1.8-MHz Doppler ultrasound (US) probe for 1 hour
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control group (no ultrasound)
Number of subjects: 37
Study: 16601292

Group type: EXPERIMENTAL
Intervention: Subsequent endocrine therapy after fulvestrant
Number of subjects: 54
Study: 16594273

Group type: EXPERIMENTAL
Intervention: Control-enhanced condition (caring for a plant)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard of care (comparison condition)
Number of subjects: 20
Study: 11225738

Group type: COMPARATOR
Intervention: School-based mental health programs
Number of subjects: 47

Group type: COMPARATOR
Intervention: Implementation features
Number of subjects: 47
Study: 9322561

Group type: EXPERIMENTAL
Intervention: 4184 kJ meal
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 2092 kJ meal
Number of subjects: 16
Study: 16350577

Group type: EXPERIMENTAL
Intervention: Testosterone (T)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dihydrotestosterone (DHT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 3161487

Group type: EXPERIMENTAL
Intervention: tocainide HC1 900 mg/day
Number of subjects: 48

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: lidocaine
Number of subjects: 48
Study: 30501605

Group type: EXPERIMENTAL
Intervention: BPF (standard bergamot polyphenolic fraction)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: BPF Phyto (phytosomal formulation of bergamot polyphenolic fraction)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 28466493

Group type: EXPERIMENTAL
Intervention: Swipe with gloved finger
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Swipe with cloth
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Wipe from wet bloodstains
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Overall classification of pattern types
Number of subjects: 12
Study: 25924202

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (OXT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 22935006

Group type: EXPERIMENTAL
Intervention: Exercise and tea catechin supplementation
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Tea catechin supplementation
Number of subjects: 128

Group type: COMPARATOR
Intervention: Health education
Number of subjects: 128
Study: 20383510

Group type: EXPERIMENTAL
Intervention: Labetalol (2.5 mg in 20 ml saline)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo (20 ml saline)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Labetalol (5 mg in 20 ml saline)
Number of subjects: 75
Study: 18619622

Group type: EXPERIMENTAL
Intervention: Extracorporeal shockwave treatment (ESWT)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Hyperbaric oxygen therapy (HBO)
Number of subjects: 72
Study: 17432639

Group type: EXPERIMENTAL
Intervention: Electroacupuncture at Dazhui (GV 14)
Number of subjects: 261

Group type: COMPARATOR
Intervention: Antondine injection (Control)
Number of subjects: 261
Study: 12799126

Group type: EXPERIMENTAL
Intervention: Usual care + nurse case manager (NCM)
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Usual care + community health worker (CHW)
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Usual care + nurse case manager/community health worker team
Number of subjects: 186

Group type: COMPARATOR
Intervention: Usual care only
Number of subjects: 186
Study: 10641772

Group type: EXPERIMENTAL
Intervention: APD treatment
Number of subjects: 34

Group type: COMPARATOR
Intervention: CAPD treatment
Number of subjects: 34
Study: 9032854

Group type: EXPERIMENTAL
Intervention: Gamma Knife radiosurgery with a mean dose of 12.1 Gy
Number of subjects: 29
Study: 1647919

Group type: EXPERIMENTAL
Intervention: Continuous total parenteral nutrition (infused continuously over 24 h)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Cyclic total parenteral nutrition (infused between 22.00 and 10.00 hours)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Both interventions (Continuous and Cyclic total parenteral nutrition)
Number of subjects: 12
Study: 6347581

Group type: EXPERIMENTAL
Intervention: Timolol 10 mg twice daily
Number of subjects: 99

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study: 3910159

Group type: EXPERIMENTAL
Intervention: Lay open treatment (n = 26)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Excision treatment (n = 21)
Number of subjects: 47
Study: 30170422

Group type: EXPERIMENTAL
Intervention: Home-based telehealth exercise training program (8-week duration, 32 sessions)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 98
Study: 27627782

Group type: EXPERIMENTAL
Intervention: Naltrexone hydrochloride, 50 mg/d
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 24967363

Group type: EXPERIMENTAL
Intervention: Physiological Cost Index (PCI) during walking over ground and on the Gait Trainer (GT) with body weight support (BWS)
Number of subjects: 12
Study: 22818074

Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve replacement (TAVR)
Number of subjects: 628

Group type: COMPARATOR
Intervention: Surgical aortic valve replacement (AVR)
Number of subjects: 628

Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve replacement (TAVR) via transapical approach
Number of subjects: 628

Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve replacement (TAVR) via transfemoral approach
Number of subjects: 628
Study: 20502223

Group type: EXPERIMENTAL
Intervention: Plavix (PG)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control (NPG)
Number of subjects: 61
Study: 17640035

Group type: EXPERIMENTAL
Intervention: Cluster-weighted Cox model
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cluster-weighted Weibull model
Number of subjects: 0
Study: 15762190

Group type: EXPERIMENTAL
Intervention: DHEA treatment (50 mg/day for 9 days)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 14696887

Group type: EXPERIMENTAL
Intervention: Ketorolac 0.35 mg x kg(‐1)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Morphine 0.1 mg x kg(‐1)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Ketorolac
Number of subjects: 50

Group type: COMPARATOR
Intervention: Morphine
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both Ketorolac and Morphine
Number of subjects: 50
Study: 10826388

Group type: EXPERIMENTAL
Intervention: Empowerment-interaction model
Number of subjects: 0
Study: 8979201

Group type: EXPERIMENTAL
Intervention: Prednisone (39 patients, 51%)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo (36 patients, 49%)
Number of subjects: 75
Study: 1476266

Group type: EXPERIMENTAL
Intervention: Oral defibrotide in association with diet and oral antidiabetic drugs
Number of subjects: 117

Group type: COMPARATOR
Intervention: Diet and antidiabetic agents (Control)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Oral defibrotide
Number of subjects: 117
Study: 6435481

Group type: EXPERIMENTAL
Intervention: Intravenous nitroglycerin (iv NTG) infusion at 0.5 microgram . kg‐1 . min‐1 for 20 min prior to induction of anesthesia and throughout the study
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 31060839

Group type: EXPERIMENTAL
Intervention: Gluten-free diet (GFD)
Number of subjects: 65
Study: 29421218

Group type: EXPERIMENTAL
Intervention: Topically delivered kynurenic acid cream
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study: 27863615

Group type: EXPERIMENTAL
Intervention: Lavender essence inhalation (2 drops at 4-5, 6-7, 8-9 cm cervical dilation)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Distilled water (placebo)
Number of subjects: 120
Study: 24672938

Group type: COMPARATOR
Intervention: HAART alone (treatment group)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: HAART combined with Qiling Decoction (combination group)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Healthy control group
Number of subjects: 55
Study: 23154391

Group type: EXPERIMENTAL
Intervention: Laparoendoscopic single-site access (LESS)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Conventional three-port laparoscopic appendectomy (TPLA)
Number of subjects: 200
Study: 19850762

Group type: EXPERIMENTAL
Intervention: Patients with PKAN
Number of subjects: 17

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 17
Study: 19029207

Group type: EXPERIMENTAL
Intervention: Bayesian approach to sample size calculations from an industry perspective
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Expected value of information methods
Number of subjects: 0
Study: 15764627

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 80

Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 80
Study: 12495231

Group type: EXPERIMENTAL
Intervention: Origami exercises
Number of subjects: 12

Group type: COMPARATOR
Intervention: Size comparison tasks only (Control)
Number of subjects: 12
Study: 10478805

Group type: EXPERIMENTAL
Intervention: Training rehabilitation (group Tr, n=20)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional rehabilitation (group C, n=20)
Number of subjects: 40
Study: 8648209

Group type: EXPERIMENTAL
Intervention: Saquinavir (600 mg, 3 times/day) alone or in combination with zidovudine (200 mg, 3 times/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Combination of saquinavir, zidovudine, and dideoxycytidine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Genotypic analysis of saquinavir resistance
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Absence of genotypic resistance
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Met90 mutation
Number of subjects: 0
Study: 1924611

Group type: EXPERIMENTAL
Intervention: Facilitative counselor condition
Number of subjects: 75

Group type: COMPARATOR
Intervention: Nonfacilitative counselor condition
Number of subjects: 75
Study: 7042029

Group type: EXPERIMENTAL
Intervention: Oral metronidazole (n = 46)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Intravenous metronidazole (n = 51)
Number of subjects: 97
Study: 31916890

Group type: EXPERIMENTAL
Intervention: Psilocybin-assisted psychotherapy
Number of subjects: 15
Study: 31157652

Group type: EXPERIMENTAL
Intervention: Crystalloid (Ringerfundin)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Colloid (6% hydroxyethyl starch, HES)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 30
Study: 27593842

Group type: EXPERIMENTAL
Intervention: Verticalization on days 2-5 post-bleeding
Number of subjects: 65

Group type: COMPARATOR
Intervention: Verticalization on day 12 post-bleeding
Number of subjects: 65
Study: 25684005

Group type: EXPERIMENTAL
Intervention: Remifentanil effect-site concentration of 1.0 ng/mL (group R1.0)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Remifentanil effect-site concentration of 1.5 ng/mL (group R1.5)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Remifentanil effect-site concentration of 0 ng/mL (group R0)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Remifentanil effect-site concentration of 0.5 ng/mL (group R0.5)
Number of subjects: 128
Study: 23672916

Group type: EXPERIMENTAL
Intervention: Computer-assisted TKA
Number of subjects: 78

Group type: COMPARATOR
Intervention: Manual TKA
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Postoperative radiographs (mechanical axis)
Number of subjects: 78
Study: 21836540

Group type: EXPERIMENTAL
Intervention: Alemtuzumab induction with tacrolimus monotherapy
Number of subjects: 123

Group type: COMPARATOR
Intervention: Daclizumab induction with tacrolimus/mycophenolate combination
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Both regimens
Number of subjects: 123
Study: 19792844

Group type: EXPERIMENTAL
Intervention: SRP plus PDT
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: SRP plus systemic doxycycline
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: SRP only
Number of subjects: 45
Study: 16772244

Group type: EXPERIMENTAL
Intervention: Low-fat milk (240 mL, 12 g of lactose)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Lactose-free milk
Number of subjects: 49
Study: 15471317

Group type: EXPERIMENTAL
Intervention: Molecular adsorbent recirculating system (MARS)
Number of subjects: 0
Study: 11370406

Group type: EXPERIMENTAL
Intervention: Amphotericin B
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fluconazole, ketoconazole, and itraconazole
Number of subjects: 0
Study: 9269944

Group type: EXPERIMENTAL
Intervention: Fixed combination of benazepril (10 mg) and low-dose amlodipine (2.5 mg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 8304707

Group type: EXPERIMENTAL
Intervention: Methylprednisolone (MePr)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Prednisolone methylsulfobenzoate (MsPr)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 57
Study: 3661923

Group type: EXPERIMENTAL
Intervention: 0.1 mg fentanyl
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 0.2 mg fentanyl
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (no fentanyl)
Number of subjects: 24
Study: 29498753

Group type: EXPERIMENTAL
Intervention: Text message-based alcohol intervention (TM)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Standard care (SC)
Number of subjects: 15
Study: 27265743

Group type: EXPERIMENTAL
Intervention: Durvalumab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Durvalumab + Tremelimumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard of Care (SoC; erlotinib, gemcitabine, or vinorelbine)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Durvalumab or Tremelimumab as monotherapy
Number of subjects: 0
Study: 25953222

Group type: EXPERIMENTAL
Intervention: Norepinephrine (0.66 mg/L)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Epinephrine (0.33 mg/L)
Number of subjects: 120
Study: 23963340

Group type: EXPERIMENTAL
Intervention: EMG triggered electrical stimulation (EMG‐ES) plus unilateral task practice
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: EMG triggered electrical stimulation (EMG‐ES) plus bilateral task practice
Number of subjects: 21

Group type: COMPARATOR
Intervention: EMG triggered electrical stimulation (EMG‐ES)
Number of subjects: 21